Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Alnylam Stops Development of Heart Failure Therapy Over Patient Deaths

By Ryan Bushey | October 7, 2016

Alnylam Pharmaceuticals announced Wednesday night it would end its development program for revusiran over startling data that indicated patients taking this drug had a higher chance of dying versus those being treated with a placebo.

Study safety monitors recommended the company suspend its Phase 3 trial when patients from a previous study developed nerve pain, reported Reuters.

An additional set of unblended data later demonstrated there was an imbalance of mortality in the revusiran arm of the study compared with the placebo group.

Alnylam, located in Cambridge, Massachusetts, specializes in RNA interference technology, which focuses on designing therapies that block genes from developing their designated proteins.

Revusiran’s purpose is to target a gene that produces an abnormal protein that induces amyloidosis. It’s a condition where amyloid plaques build up in organs like the heart leading to heart failure.

“Patient safety comes first. We have stopped all dosing and are actively monitoring patients across revusiran studies to ensure their safety. We will also continue to evaluate ENDEAVOUR data to understand the potential cause of these findings,” said John Maraganore, Ph.D., and Alnylam CEO in a statement.

About 206 people were enrolled in this study in which 18 died due to heart-related issues. Analysts believed the drug was slated to be a blockbuster within the next decade, explained FierceBiotech.

Other development programs under Alnylam’s umbrella are continuing without issue, but the company’s stock still plummeted more than 40 percent in after-hours trading.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE